Stephen Stahl

Stephen M. Stahl is a medical professional who holds undergraduate and medical degrees from North-western University in Chicago, where he was a member of the Honors Program in Medical Education. He also holds a Ph.D. degree in pharmacology and physiology from the University of Chicago. Dr. Stahl has received training in three different medical specialties, namely internal medicine at the University of Chicago, neurology at the University of California in San Francisco, and psychiatry at Stanford University. He is board certified in psychiatry.[5][6]

Dr. Stahl has conducted numerous research projects during his career, which have been awarded by the National Institute of Mental Health (NIMH), the Department of Veteran Affairs (VA), and the pharmaceutical industry. He is dedicated to producing and disseminating educational information about diseases and their treatments in psychiatry and neurology, which is a major area of his interest. He conducted research on various topics such as the effectiveness of St John's wort in major depression through a randomized controlled trial, a review of the current nomenclature for psychotropic agents, and an introduction to the Neuroscience-based Nomenclature.[7] Additionally, his team researched on the evolution of GABA A receptor modulators as hypnotics in their search for perfect sleep.[8]

Dr. Stahl has held faculty positions at several prestigious universities, including Stanford University, the University of California at Los Angeles (UCLA), the Institute of Psychiatry London, and the Institute of Neurology London. He is currently a Health Sciences Clinical Professor of Psychiatry and Neuroscience at the University of California Riverside, as well as an Adjunct Professor of Psychiatry at the University of California San Diego and at the State University of New York Upstate Medical University at Syracuse.[9][10] He is also an Honorary Visiting Senior Fellow at the University of Cambridge in the United Kingdom. Dr. Stahl is the Director of psychopharmacology services and academic programs for the California Department of State Hospital System, which has five facilities and serves 6500 patients. He plays a leadership role in addressing violence and the decriminalization of the seriously mentally ill. Previously, he served as the Executive Director of Clinical Neurosciences at the Merck Neuroscience Research Center in the UK for several years.[11]

Dr. Stahl is serving as an editorial board member of several international reputed journals including International Review of Psychiatry, Journal of Psychiatry in Clinical Practice, Neuropsychopharmacology, Journal of Psychotic Disorders, Clinical Neuropsychiatry, Psychiatry/Innovations in Clinical Neuroscience, Expert Opinion on Pharmacotherapy, Acta Psychiatrica Scandinavica, therapeutic Advances in Psychopharmacology, Neuropsychiatry, Frontiers in Psychopharmacology. He has written over 60 textbooks and edited 15 others, including the best-selling and award-winning textbook, Stahl’s Essential Psychopharmacology, now in its fifth edition. He has also served on numerous medical and scientific advisory boards for various organizations, including the pharmaceutical industry, biotechnology and medical information industry, and non-profit and public service organizations.

• Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 5 th edition, Cambridge University Press, New York, 202 ISBN 978-1107025981[12]
• Stahl SM. Stahl’s Essential Psychopharmacology: The Prescriber’s Guide, 7th edition, Cambridge University Press, New York, 2021[13]
• Stahl's Illustrated Antipsychotics: Treating Psychosis, Mania and Depression. ISBN 13: 978-0521149051[14]
• Stahl's Illustrated Anxiety, Stress, and PTSD. ISBN 978-0521153997[15]
• Stahl's Self-Assessment Examination in Psychiatry: Multiple Choice Questions for Clinicians. ISBN 978-1316502495
• Stahl's Illustrated Chronic Pain and Fibromyalgia. ISBN 978-0521133227

• Fava M, Stahl SM, De Martin S, Mattarei A, Bettini E, Comai S, Alimonti A, Bifari F, Pani L, Folli F, Guidetti C, Furlan A, Sgrignani J, Locatelli P, Cavalli A, O'Gorman C, Traversa S, Inturrisi CE, Pappagallo M, Manfredi PL. Esmethadone-HCl (REL-1017): a promising rapid antidepressant. Eur Arch Psychiatry Clin Neurosci. 2023 Mar 8.[16]
• Dodd S, Norman TR, Carvalho AF, Eyre H, Stahl SM, Berk M. Psilocybin in Neuropsychiatry: A Review of its Pharmacology, Safety and Efficacy, 2022, CNS Spectrums.[17]
• Yohn, S, Weiden P Felder CC and Stahl SM, Muscarinic acetylcholine receptors for psychotic disorders: bench-side to clinic, Trends in Pharmacological Sciences, 2022, Vol. 43, No. 12.[18]
• S2022 Cooper T, Seigler M, Stahl SM, Rapid onset brain plasticity at novel pharmacologic targets hypothetically drives innovations for rapid onset antidepressant actions, J Psychopharmacol.[19]
• McIntyre RS, Rosenblat JD, Nemeroff CB, Sanacora G, Murrough JW, Berk M, Brietzke E, Dodd S, Gorwood P, Ho R, Iosifescu DV, Jaramillo CL, Kasper S, Kratiuk K, Lee JG, Lee Y, Lui LMW, Mansur RB, Papakostas GI, Subramaniapillai M, Thase M, Vieta E, Young AH, Zarate CA, Stahl SM. Synthesizing the Evidence for Ketamine and Esketamine in Treatment Resistant Depression: Guidance and International Perspective, Am J Psychiatry.[20]
• Meltzer HY, Stahl SM. The dopamine hypothesis of schizophrenia: a review. Schizophr Bull. 1976;2(1):19-76.[21]
• Stahl SM, Pradko JF, Haight BR, Modell JG, Rockett CB, Learned-Coughlin S. A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor. Prim Care Companion J Clin Psychiatry. 2004;6(4):159-166.[22]